Jeremy M. Levin
Known title: CEOCIK: 0001256153
Jeremy M. Levin's purchase track record
Jeremy M. Levin has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/18/2024 | OVID | $50K | -71.1% | -57.1% | +9.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| OVID | ▲ Buy | Option Exercise | 47,333 | $66K | 3/23/2026 | View on chart |
| OVID | ▼ Sell | Other | 71,000 | — | 12/15/2025 | View on chart |
| OVID | ▲ Buy | Open Market | 18,248 | $50K | 3/18/2024 | View on chart |
| OVID | ▼ Sell | Gift | 573,275 | $0 | 12/4/2023 | View on chart |
| OVID | ▼ Sell | Gift | 573,275 | $0 | 12/4/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Ovid Therapeutics shares decline in pre-market session
Ovid Therapeutics stock fell during Tuesday's pre-market trading, joining a group of larger companies experiencing similar declines. The drop brings the stock closer to its recent support level of $2.38. This movement occurs while the average analyst price target remains significantly higher at $5.92.
Ovid Therapeutics shares decline in pre-market session. Ovid Therapeutics stock fell during Tuesday's pre-market trading, joining a group of larger companies experiencing similar declines. The drop brings the stock closer to its recent support level of $2.38. This movement occurs while the average analyst price target remains significantly higher at $5.92.